DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Digitek (Digoxin) - Summary

 
 



DIGITEK SUMMARY

DIGITEK (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of Digitalis lanata. The term "digitalis" is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence "glycosides").

Heart Failure:    DIGITEK is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified.

Atrial Fibrillation:    DIGITEK is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation.


See all Digitek indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Digitek (Digoxin)

Heart Drug Digoxin May Not Be Best for Some Heart Patients
Source: MedicineNet Calcium Channel Blockers Specialty [2015.05.06]
Title: Heart Drug Digoxin May Not Be Best for Some Heart Patients
Category: Health News
Created: 5/5/2015 12:00:00 AM
Last Editorial Review: 5/6/2015 12:00:00 AM

Skeletal muscle atrophy in congestive heart failure
Source: Bones / Orthopedics News From Medical News Today [2015.08.12]
MDC and Charité researchers elucidate mechanismIt is a paradox: Patients with advanced congestive heart failure lose skeletal muscle mass, but their heart muscles become enlarged to provide the...

Congestive Heart Failure (CHF)
Source: MedicineNet Pneumococcal Vaccination Specialty [2014.12.29]
Title: Congestive Heart Failure (CHF)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/29/2014 12:00:00 AM

Congestive Heart Failure
Source: MedicineNet Impotence (ED) Specialty [2013.10.08]
Title: Congestive Heart Failure
Category: Diseases and Conditions
Created: 10/16/2013 7:54:00 PM
Last Editorial Review: 10/8/2013 12:00:00 AM

more news >>

Published Studies Related to Digitek (Digoxin)

Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. [2014]
To investigate the impact of the direct Factor Xa inhibitor darexaban administered in a modified-release formulation (darexaban-MR) on the pharmacokinetic (PK) profile of digoxin. In this Phase I, randomized, double-blind, two-period crossover study (8 days for each treatment, 10 days washout), 24 healthy subjects received darexaban-MR 120 mg once/day (qd) + digoxin 0.25 mg qd in one treatment period, and placebo + digoxin 0.25 mg qd in the other treatment period...

Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial. [2014]
with lacosamide or placebo... CONCLUSION: Co-administration of steady-state digoxin (0.25 mg/day) with

The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. [2012]
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. [2011.03]
The aim of this study was to investigate whether multiple doses of the oral and highly selective dipeptidyl peptidase-4 inhibitor linagliptin affect the steady-state pharmacokinetics of the P-glycoprotein substrate digoxin. This single-center, open-label, two-period cross-over study involved healthy subjects (n = 20), randomized to treatment sequence AB or BA, where A comprised 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days, and B comprised 0.25 mg digoxin qd for 11 days...

Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011.01.19]
CONCLUSIONS: Although hemodynamic disturbances play a role in the overall pathogenesis of respiratory distress syndrome, the specific contribution of early congestive heart failure (unrelated to hemodynamically significant patent ductus arteriosus) does not appear to be a significant factor in RDS. Treatment with digoxin has no proven value in infants solely affected with RDS.

more studies >>

Clinical Trials Related to Digitek (Digoxin)

Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care [Completed]
Dosing methods for digoxin, a drug used to treat heart failure, have not been updated in decades despite evidence in recent years suggesting that blood levels of digoxin achieved with traditional dosing practices may increase the risk of adverse events. We developed a simple dosing tool that targets lower blood levels of digoxin that have been associated with improved outcomes compared to higher blood levels. The aim of this study is to determine if this simplified dosing tool is more effective than standard digoxin dosing practices at achieving lower blood levels and also to determine if digoxin dosing may be further optimized by incorporating patients' genetic information believed to influence the drug's properties.

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects [Completed]
The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

Drug Interaction Study of Isavuconazole and Digoxin [Completed]

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults [Completed]
The primary objective of this study is to determine the effect of repeat oral doses of eliglustat 150 mg twice daily (BID) (or 100 mg BID for CYP2D6 poor metabolizers) on the pharmacokinetics (PK) of orally administered digoxin 0. 25 mg in healthy adult subjects. This will be a single-site, open-label study in 2 staggered cohorts of healthy adult subjects.

The study will comprise a screening period (between Day - 45 and Day -2), treatment period 1

(Day - 1 to Day 4), treatment period 2 (Day 11 to Day 18), and a safety follow-up visit (Day

24 ± 1). There will be a 10-day washout between dosing of study drug in Period 1 and Period 2. The duration of each subject's participation in the study, inclusive of the screening and follow-up visits, will be approximately 10 weeks.

to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers [Completed]
The aim of this trial is to investigate the effect of multiple doses of flibanserin on the single dose pharmacokinetics of digoxin in healthy female and male volunteers. Digoxin is a narrow therapeutic index drug for which a large number of relevant drug-drug interactions are known. Flibanserin is now under evaluation in postmenopausal women which increases the likelihood that flibanserin and digoxin will be administered together in the clinical setting.

more trials >>


Page last updated: 2015-08-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015